views

SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31^st December 2021 which show revenue of just £21,949, cash £1.5 million lower to £3.2 million and include a warning that full-year forecasts will be materially missed – and the shares have responded down to 35p. But here’s why we retain significant confidence and see this as a buying opportunity. From here this could be a 10 bagger.

NEWSFLOW

views

SkinBioTherapeutics (SBTX) has published a “Business update” announcement including that it has now progressed to the second phase of its AxisBiotix-Ps food supplement for psoriasis product commercialisation strategy and that the SkinBiotix active ingredient project with Sederma is on track. Sounds good!

NEWSFLOW

views

SkinBioTherapeutics (SBTX) has announced results for its year ended 30^th June 2021 emphasising “transformational” progress. So what is this?

views

Having been falling from early this month, shares in SkinBioTherapeutics (SBTX) are currently further lower after it announced “OptiBiotix Health Plc has placed 3,636,363 ordinary shares in SkinBioTherapeutics with new and existing institutional investors at a price of 55 pence per share”. With SkinBioTherapeutics CEO Stuart Ashman though arguing “the company is going from strength to strength” and “it is important to attract new investors who are keen to come on board to support us in the next stage of the company's development, as a commercial entity”, why the further share price fall?

NEWSFLOW

views

SkinBioTherapeutics (SBTX) has announced it has commercially launched its probiotic food supplement to help alleviate the symptoms associated with psoriasis, AxisBiotix-Ps.

NEWSFLOW

views

As things stand at 69p, we are 289% ahead on this share tip but there is much more to come. SkinBioTherapeutics (SBTX) has announced its probiotic food supplement to help alleviate the symptoms of psoriasis, AxisBiotix-Ps, is to launch on 29^th October, following highly positive results from its consumer study in May and key commercialisation activities since.